Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
COX-2 Inhibitor
COX-2-IN-27 is a potent and selective inhibitor of cyclooxygenase-2 (COX-2), exhibiting an IC50 of 0.045 µM against COX-2, while demonstrating significantly higher IC50 values of 13.22 µM for COX-1 and 1.67 µM for 15-lipoxygenase (15-LOX). This compound exhibits notable anti-inflammatory activity, making it a valuable tool for research in inflammation-related pathways and the study of COX-2 mediated processes. Its selectivity enables detailed investigations into the role of COX-2 in disease and therapeutic applications. -
COX-1 Inhibitor
VU0487836 is a selective inhibitor of cyclooxygenase-1 (COX-1), exhibiting an IC50 value of 0.36 μM against ovine-derived COX-1. This compound is being investigated as a prototype for developing radiological imaging agents aimed at COX-1 in ovarian cancer. VU0487836 is relevant for research focused on ovarian cancer and may provide insights into therapeutic strategies targeting COX-1 pathways. -
COX-2 Inhibitor
LM-4108 (N-(2-Phenylethyl)-indomethacin amide) is a selective and orally active inhibitor of COX-2, demonstrating an IC50 of 0.06 μM against purified human COX-2. This compound exhibits significant anti-inflammatory properties and has potential applications in cancer prevention. The metabolic stability of LM-4108 varies across species, with half-lives of 11 minutes in rat, 21 minutes in human, and 51 minutes in mouse liver microsomes. -
COX-2 Inhibitor
COX-2-IN-5 is a selective inhibitor of cyclooxygenase-2 (COX-2), exhibiting an IC50 value of 0.65 µM. This compound is primarily utilized in research focused on inflammation and related pathways. Its potent inhibitory activity makes it an invaluable tool for studying COX-2 mediated processes in various biological contexts. -
COX-2/5-LOX Inhibitor
COX-2/5-LOX-IN-2 is a potent dual inhibitor of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX). This benzothiophen-2-yl pyrazole carboxylic acid derivative demonstrates significant analgesic and anti-inflammatory properties, exhibiting COX-2 inhibitory activity with an IC50 of 0.01 μM and 5-LOX inhibitory activity with an IC50 of 1.78 μM. COX-2/5-LOX-IN-2 is a valuable tool for research applications aimed at understanding and modulating inflammatory pathways. -
COX Inhibitor
Plantanone A is a selective cyclooxygenase (COX) inhibitor, demonstrating an IC50 of 33.37 μM for ovine COX-1 and 46.16 μM for ovine COX-2. This compound exhibits limited DPPH radical scavenging activity with an IC50 of 467.7 μM. Plantanone A serves as a valuable tool for investigating inflammation-related diseases and their underlying mechanisms. -
COX-2 Inhibitor
COX-2-IN-17 is a potent inhibitor of cyclooxygenase-2 (COX-2) with a remarkable ability to penetrate the blood-brain barrier (BBB), exhibiting an IC50 of 0.02 μM. This compound demonstrates significant anti-inflammatory and analgesic properties, effectively reducing hyperalgesia during both the neurogenic and inflammatory phases. COX-2-IN-17 is suitable for research applications aimed at understanding pain mechanisms and exploring potential therapeutic interventions for inflammatory conditions. -
COX-1/2 Inhibitor
N-Acetyl-2-carboxybenzenesulfonamide is a potent inhibitor of COX-1 and COX-2, exhibiting IC50 values of 0.06 μM and 0.25 μM, respectively. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for the study of inflammatory pathways and the development of anti-inflammatory therapies. Its ability to selectively inhibit cyclooxygenase enzymes positions it as a useful agent in pharmacological research. -
COX-2 Inhibitor
COX-2-IN-51 is a selective COX-2 inhibitor exhibiting an IC50 of 70.7 nM. It effectively reduces LPS-induced release of nitric oxide (NO) and prostaglandin E2 (PGE2), as well as the expression of COX-2 and inducible nitric oxide synthase (iNOS), and inhibits the NF-κB signaling pathway. This compound demonstrates anti-inflammatory and analgesic properties in various murine models by targeting the NF-κB cascade, while presenting a lower risk of gastrointestinal side effects compared to traditional nonsteroidal anti-inflammatory drugs. -
COX-I Inhibitor
2,5-Dimethoxy-3-glucopyranosylcinnamic alcohol is a selective inhibitor of the cyclooxygenase-1 (COX-I) enzyme. This compound exhibits notable anti-inflammatory properties, making it a valuable tool for research in inflammation-related pathways. It is isolated from the plant species P. crocatum and Dirca palustris and can be utilized in studies investigating the modulation of inflammatory responses and related signaling mechanisms. -
COX Inhibitor
Pemedolac is a selective inhibitor of cyclooxygenase (COX), demonstrating potent analgesic activity while minimizing anti-inflammatory effects. This compound exhibits significant efficacy in alleviating chemically induced and inflammatory pain in preclinical models, with effective pain relief achieved at lower doses than those typically associated with anti-inflammatory or gastric irritant effects. Pemedolac has a reduced ulcerogenic potential, suggesting a safer profile compared to standard nonsteroidal anti-inflammatory drugs (NSAIDs), making it a valuable candidate in the treatment of neurological, dermatological, and musculoskeletal disorders. -
COX-1 Inhibitor
COX-1-IN-4 is a selective inhibitor of cyclooxygenase-1 (COX-1), demonstrating an IC50 of 0.09 μM for COX-1 and 2.49 μM for COX-2. This compound effectively reduces nitric oxide production and decreases the expression of the inducible nitric oxide synthase (iNOS) protein. COX-1-IN-4 is valuable for exploring mechanisms associated with neuroinflammation in research settings. -
COX-2 Inhibitor
COX-2-IN-47 is a selective inhibitor of cyclooxygenase-2 (COX-2), exhibiting an IC50 value of 0.03 μM. This compound demonstrates notable anti-edema activity, making it valuable for research in inflammation and pain management studies. COX-2-IN-47 can be utilized to explore pathways involving COX-2 modulation in various biological contexts. -
COX1/2 Inhibitor
COX-1/2-IN-1 is a selective inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), exhibiting significant anti-inflammatory properties. It demonstrates IC50 values of 13.9 ± 3.21 µM for COX-1 and 6.4 ± 0.74 µM for COX-2, effectively modulating prostaglandin synthesis. This compound is valuable for research related to pain, inflammation, and cardiovascular disorders. -
COX-2 Inhibitor
Clematomandshurica saponin B is a selective inhibitor of cyclooxygenase-2 (COX-2), exhibiting significant inhibitory activity with an IC50 of 2.58 mM. This compound's ability to modulate COX-2 activity makes it valuable for studying inflammatory processes and analgesic pathways in various biological systems. It can serve as a tool for research applications focused on understanding pain mechanisms and developing anti-inflammatory therapies. -
COX-2 Inhibitor
Vitacoxib is a selective COX-2 inhibitor, functioning primarily through the blockade of cyclooxygenase-2 enzyme activity. This compound exhibits significant anti-inflammatory properties, making it a valuable tool for studying inflammatory diseases. Vitacoxib can also be employed in pain and fever research applications, contributing to a deeper understanding of these conditions. -
COX-2/sEH Inhibitor
COX-2/sEH-IN-1 is a dual inhibitor targeting cyclooxygenase-2 (COX-2) and soluble epoxide hydrolase (sEH), with IC50 values of 1.24 µM and 0.40 nM, respectively. This compound exhibits enhanced anti-inflammatory properties and significantly lowers cardiovascular risks. COX-2/sEH-IN-1 is suitable for research applications aimed at understanding inflammatory pathways and developing therapeutic strategies for cardiovascular diseases. -
COX-2 Inhibitor
COX-2-IN-13 is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 of 0.98 μM. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research into inflammation and pain pathways. Additionally, COX-2-IN-13 demonstrates a favorable safety profile in in vivo acute toxicity studies, supporting its potential use in therapeutic applications. -
COX-2 Inhibitor
COX-2-IN-11 is a potent and selective inhibitor of cyclooxygenase-2 (COX-2), involved in the inflammatory response. This compound exhibits significant anti-inflammatory activity, making it valuable for studies on inflammation-related diseases. Research applications may include investigating the role of COX-2 in various pathological conditions and exploring therapeutic strategies for inflammatory disorders. -
COX-2/15-LOX Inhibitor
COX-2/15-LOX-IN-5 is a potent dual inhibitor of cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX). This compound effectively attenuates lipopolysaccharide-induced NF-κB activation in RAW 264.7 macrophages, highlighting its role in modulating inflammatory responses. COX-2/15-LOX-IN-5 exhibits significant anti-inflammatory and antioxidant properties, making it a valuable tool for research into inflammatory diseases and other related biological processes. -
COX-2 Inhibitor
COX-2-IN-16 is a potent and selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 of 102 µM. This compound effectively inhibits nitric oxide (NO) production and exhibits significant anti-inflammatory activity. COX-2-IN-16 is suitable for research applications focused on inflammation and pain pathways. -
COX Inhibitor
Florifenine is a selective cyclooxygenase (COX) inhibitor that demonstrates significant anti-inflammatory activity. It effectively inhibits thromboxane B2 (TXB2) production in human whole blood with an IC50 value of 32.5 nM. Florifenine has been shown to reduce neutrophil migration and lower prostaglandin E2 (PGE2) levels in inflamed tissues, including ear edema and air pouch inflammation induced by Zymosan. This compound serves as a valuable tool for investigations in anti-inflammatory research. -
Lipoxygenase/COX Inhibitor
SKF-105809 is a dual inhibitor of lipoxygenase and cyclooxygenase (COX), targeting key enzymes involved in the inflammatory pathway. This compound demonstrates a significant reduction in edema and inflammatory cell infiltration in murine models of ear, paw, and peritoneal inflammation. Additionally, SKF-105809 reduces the production of acute-phase reactive proteins in models of arthritis and exhibits analgesic effects in abdominal contraction assays while preventing ulceration. Its applications extend to the study of inflammatory and immune system disorders, including peritonitis and arthritis. -
COX-2 Inhibitor
COX-2-IN-14 is a highly selective inhibitor of cyclooxygenase-2 (COX-2). This compound demonstrates effective binding at the active site of COX-2, as confirmed by co-crystal studies. In vivo, COX-2-IN-14 exhibits significant anti-inflammatory properties, notably reducing ear edema and myeloperoxidase (MPO) activity in mouse models. It serves as a valuable tool for research into inflammatory processes and the development of treatments targeting COX-2-related conditions. -
COX-1/2 Inhibitor
K-80001 is a selective COX-1/2 inhibitor that demonstrates potent inhibition with IC50 values of 82.9 μM, 3.4 μM, and 1.2 μM against RXRα, COX-1, and COX-2, respectively. Its mechanism involves binding to the RXRα receptor, contributing to its pharmacological profile. K-80001 is primarily utilized in studies focusing on pain management and inflammatory processes, making it a valuable tool for researchers investigating the roles of cyclooxygenases in various biological contexts. -
COX-2 Inhibitor
Parameritannin A-1 is a tetrameric proanthocyanidin (PAC) that selectively inhibits cyclooxygenase-2 (COX-2). Isolated from the bark of Parameria laevigata Moldenke, this compound exhibits anti-inflammatory properties and is valuable for studies related to inflammatory diseases. Additionally, Parameritannin A-1 has been shown to inhibit phospholipase A2 (PLA2) activity, further supporting its potential applications in biochemical research involving inflammatory pathways and lipid metabolism. -
COX-2 Inhibitor
Lefucoxib is a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in the inflammatory process. This compound demonstrates significant anti-inflammatory activity, making it valuable for research applications related to osteoarthritis and rheumatoid arthritis. Its selective targeting of COX-2 allows for a focus on the inflammatory pathways involved in these conditions. -
COX-1/2 Inhibitor
COX-1/2-IN-3 is an inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). This compound exhibits significant anti-inflammatory activity while maintaining a low toxicity profile. It serves as a valuable tool for research in inflammation and pain pathways, providing insights into therapeutic applications for inflammatory diseases. -
COX-2/TAK1-NF-κB Inhibitor
BPD is a selective inhibitor of COX-2 and TAK1-NF-κB, exhibiting an IC50 of 18.5 μM for COX-2. This compound effectively reduces the transcriptional expression of key pro-inflammatory cytokines, including iNOS, TNF-α, IL-6, and IL-1β, thereby demonstrating notable anti-inflammatory properties. BPD has been shown to inhibit carrageenan-induced paw edema and mitigate LPS-induced septic mortality, making it a valuable tool for research in inflammation and related pathways. -
COX-1 Inhibitor
Parsalmide is a COX-1 inhibitor that exhibits oral activity as a non-steroidal anti-inflammatory and gastroprotective agent, demonstrating an IC50 value of 9.92 μM for COX-1 and 155 μM for COX-2. This compound effectively prevents gastric injury and reduces edema, making it valuable for studies related to arthritis and inflammation. Its dual-action profile positions Parsalmide as a promising candidate for research focused on gastrointestinal protection alongside anti-inflammatory applications. -
COX-2/PI3K Inhibitor
COX-2/PI3K-IN-2 is a potent inhibitor targeting both COX-2 and PI3K pathways, exhibiting an IC50 value of 2.78 nM for PI3K and a Ki value of 3.02 nM for COX-2. This compound demonstrates significant anti-inflammatory and anti-cancer activities, making it valuable for research in oncology and inflammatory disease studies. Its dual-target mechanism provides insights into the therapeutic potential of modulating these critical pathways. -
COX-2 inhibitor
Lixadesiran is an siRNA designed to inhibit cyclooxygenase-2 (COX-2) by targeting its mRNA. This compound is part of the STP705 formulation, which includes two siRNA oligonucleotides, with Pixofisiran targeting TGF-β1. Lixadesiran's mechanism of action contributes to the modulation of inflammatory pathways, making it relevant for research in cancer and fibrosis studies. -
COX Inhibitor
Murraol is a coumarin compound that acts as a cyclooxygenase (COX) inhibitor. It exhibits inhibitory effects on both COX and lipoxygenase enzymatic activities, contributing to its potential anti-inflammatory properties. Additionally, Murraol demonstrates an inhibitory effect on the growth of cancer cells, making it a valuable tool for cancer research and therapeutic investigations. -
COX Inhibitor
4-Methylamino antipyrine hydrochloride is a COX inhibitor and an active metabolite of Metamizole, a pyrazolone non-steroidal anti-inflammatory drug (NSAID). It exhibits analgesic and antipyretic properties, making it useful in the management of pain and fever. While its anti-inflammatory effects are relatively weak, this compound serves as an important tool in research applications focusing on pain relief and inflammatory pathways. -
COX Inhibitor
Pifoxime is a potent inhibitor of cyclooxygenase (COX-1 and COX-2), classified as a non-steroidal anti-inflammatory drug (NSAID). It demonstrates significant anti-inflammatory properties, making it suitable for various research applications, including neuropsychiatric studies. Pifoxime's ability to modulate inflammation can provide valuable insights into the underlying mechanisms of inflammatory processes in different biological contexts. -
COX-2 Inhibitor
Esculentic acid is a selective inhibitor of cyclooxygenase-2 (COX-2), exhibiting significant anti-inflammatory properties. As a pentacyclic triterpenoid derived from the Chinese herb Phytolacca esculenta, it is valuable in research focused on inflammation and related pathways. This compound is applicable in studies targeting the modulation of COX-2 activity and its implications in various inflammatory conditions. -
COX Inhibitor
SC-75416 is a selective inhibitor of cyclooxygenase-2 (COX-2), primarily designed to mitigate pain and inflammation. Its pharmacokinetic/pharmacodynamic (PK/PD) model has been utilized to develop clinical trial simulations that support its analgesic efficacy, demonstrated to exceed that of ibuprofen in post-oral surgery pain models. The results from these simulations and subsequent clinical trials indicate that SC-75416 offers superior pain relief, underscoring its potential as a valuable therapeutic agent for managing postoperative pain. -
COX-1/2 Inhibitor
Diclofenac amide is a prodrug that functions as an oral inhibitor of cyclooxygenase-1 and -2 (COX-1/2), effectively reducing the synthesis of prostaglandins and thromboxanes. This compound demonstrates significant anti-inflammatory activity in the carrageenan-induced rat paw edema model while preserving gastric integrity, making it a valuable tool for studying inflammation and pain mechanisms. Its favorable safety profile and effectiveness position it as a promising candidate in pharmacological research. -
COX Inhibitor
Bromfenac is a potent and orally active inhibitor of cyclooxygenases (COX-1 and COX-2), exhibiting IC50 values of 5.56 nM and 7.45 nM, respectively. This selective COX inhibition makes Bromfenac valuable in the study of ocular inflammation and pain management. Its effectiveness in reducing inflammation positions it as a useful tool for researchers investigating inflammatory pathways in various biological contexts. -
COX Inhibitor
Naproxen ethyl ester is a nonsteroidal anti-inflammatory drug that functions primarily as a cyclooxygenase (COX) inhibitor. This compound effectively alleviates pain, fever, swelling, and stiffness by obstructing the actions of COX enzymes. The R-(-)-isomer of Naproxen ethyl ester is noted for its enhanced immunogenicity, demonstrating a Michaelis-Menten constant (K(M)) of 6.67 mM and exhibiting a catalytic efficiency that is 5.8 x 10^4 times greater than that of non-catalytic reactions. This compound is useful in pain management and inflammation research. -
COX-1 Inhibitor
COX-1-IN-5 is a highly selective COX-1 inhibitor, demonstrating an IC50 of 1 nM for COX-1 and greater than 0.1 μM for COX-2, thereby showing over 1000-fold selectivity for COX-1. This compound exhibits significant anti-inflammatory, antipyretic, analgesic, antithrombotic, and potential anti-cancer properties. COX-1-IN-5 is suitable for investigating COX-mediated diseases, including inflammatory conditions and pain. Additionally, when radiolabeled with 11C, it serves as a selective PET tracer for in vivo imaging of COX-1 distribution and target engagement. -
COX Inhibitor
Flunoxaprofen is an orally active cyclooxygenase (COX) inhibitor that exhibits significant anti-inflammatory properties. In preclinical models, such as rat paw edema assays, Flunoxaprofen has demonstrated efficacy in reducing inflammation. This compound may be utilized in research focused on immune system disorders, including arthritis and related inflammatory conditions. -
COX-2 Inhibitor
COX-2-IN-19 is a potent inhibitor of cyclooxygenase-2 (COX-2), exhibiting an IC50 value of 1.76 μM. This compound demonstrates significant in vivo anti-inflammatory activity, making it a valuable tool for research in inflammation and pain pathways. COX-2-IN-19 is suitable for studies focused on the modulation of COX-2-related biological processes in various disease models. -
COX Inhibitor
COX-1/2-IN-4 is a dual inhibitor of cyclooxygenase enzymes COX-1 and COX-2, exhibiting IC50 values of 0.239 μM and 0.191 μM, respectively. This compound demonstrates moderate anticancer activity against COLO205 and B16F1 cancer cell lines, with IC50 values of 30.79 μM and 74.15 μM. It serves as a valuable tool for research into the roles of COX enzymes in inflammation and cancer. -
COX-2/15-LOX Inhibitor
COX-2/15-LOX-IN-1 is a dual inhibitor of cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX), exhibiting IC50 values of 10.65 μM for COX-1, 0.075 μM for COX-2, and 2.98 μM for 15-LOX. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research into inflammatory pathways and related diseases. Its ability to modulate key enzymes involved in arachidonic acid metabolism positions COX-2/15-LOX-IN-1 as a promising candidate for therapeutic investigation in inflammatory conditions. -
COX-2 Inhibitor
COX-2-IN-34 is a selective and orally active inhibitor of cyclooxygenase-2 (COX-2), exhibiting an IC50 of 0.42 μM. This compound demonstrates anti-inflammatory properties without the associated gastric ulcer toxicity often seen with non-selective COX inhibitors. COX-2-IN-34 is suitable for research applications focused on inflammation and related pathways. -
COX Inhibitor
ZXX2-77 is a selective inhibitor of cyclooxygenase-1 (COX-1) from the benzenesulfonylanilide compound class. It demonstrates significant COX-1 inhibitory activity in vitro, making it a candidate for pain management without the gastrointestinal side effects commonly associated with traditional analgesics. While its low oral absorption contributes to a reduced analgesic effect in vivo, its unique profile highlights the potential for developing effective COX-1 selective inhibitors that mitigate gastric damage. Further exploration of ZXX2-77 and its derivatives may lead to new therapeutic options for pain relief. -
COX-2 Inhibitor
COX-2-IN-40 is a selective COX-2 inhibitor with an IC50 value of 14.86 μM. This compound is primarily utilized in the investigation of chronic pain mechanisms and related therapeutic approaches. Its inhibition of COX-2 activity makes it a valuable tool for research into inflammatory processes and pain management strategies. -
COX-2 Inhibitor
COX-2-IN-29 is a selective inhibitor of cyclooxygenase-2 (COX-2), exhibiting an IC50 of 0.005 μM. This compound demonstrates significant anti-inflammatory activity, making it valuable in research focusing on pain modulation and inflammatory disease models. Its oral bioavailability further supports its potential utility in pharmacological studies and therapeutic applications targeting COX-2-related pathways. -
COX-2 Inhibitor
Mefenamic acid-d4 is a deuterated form of Mefenamic acid, which acts as a selective competitive inhibitor of cyclooxygenase-2 (COX-2). This NSAID exhibits significant anti-inflammatory properties, with a notable ability to penetrate the blood-brain barrier. Mefenamic acid-d4 is primarily utilized in pharmacokinetic studies and metabolic research, aiding in the exploration of inflammatory responses and mechanisms of pain relief through its interaction with COX-1 and COX-2 enzymes.
